These findings were also confirmed using mRNA expression analysis, suggesting that co‐expression of HER2 with ATM factors may be potential molecular biomarkers for predicting bladder cancer prognosis and disease aggressiveness. The gene discussed is ERBB2; the disease is urinary bladder carcinoma.